Protagonist Therapeutics, Inc (PTGX): who owns it and who trades it
As of Nov 12, 2026, PTGX insiders reported 36 open-market sales worth $87.7M and no purchases in the last 12 months, with 59% of the sale value made under pre-set 10b5-1 plans. The largest seller was Dinesh V Ph D Patel (CEO), with $53.1M. 2 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 12, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Protagonist Therapeutics
From the latest filingsOverall: more selling than buying. Insiders mostly sold. Funds mostly bought. Famous investors was close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns PTGX
342 funds and institutions reported PTGX shares worth $9.4B at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is BlackRock, Inc. with 16.0%.
Funds and institutions (13F) about 100%Everyone else 0%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| BlackRock, Inc. | 10.31M | 16.03% | $1.3B | +5% |
| Farallon Capital Management, L.l.c. | 6.35M | 9.87% | $778M | No change |
| Rtw Investments, LP | 5.06M | 7.87% | $620M | No change |
| Vanguard Portfolio Management LLC | 3.63M | 5.64% | $445M | +4% |
| Wellington Management Group LLP | 3.42M | 5.31% | $419M | -5% |
| UBS Group AG | 3.40M | 5.29% | $417M | -34% |
| State Street Corp | 3.32M | 5.16% | $407M | +7% |
| Vanguard Capital Management LLC | 2.85M | 4.44% | $350M | +2% |
| Johnson & Johnson | 2.45M | 3.81% | $300M | No change |
| Invesco Ltd. | 2.34M | 3.64% | $287M | +8% |
| T. Rowe Price Associates | 2.15M | 3.34% | $264M | +29% |
| Jupiter Topco LLC | 2.13M | 3.31% | $261M | – |
| Geode Capital Management, LLC | 1.74M | 2.71% | $213M | +4% |
| Woodline Partners LP | 1.41M | 2.20% | $173M | No change |
| Bank of America Corp | 1.32M | 2.06% | $162M | +2% |
| Jennison Associates LLC | 1.15M | 1.79% | $141M | +7% |
| Perceptive Advisors LLC | 981,879 | 1.53% | $120M | -20% |
| ADAR1 Capital Management, LLC | 960,863 | 1.49% | $118M | -3% |
| Morgan Stanley | 905,992 | 1.41% | $111M | -11% |
| Alyeska Investment Group, L.P. | 889,298 | 1.38% | $109M | +50% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, PTGX insiders reported $0 of open-market purchases and $87.7M of sales. 59% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | Asif Ali | CFO | Sale plan | 12,595 | $141.77 | $1.8M | Form 4 |
| Sep 30, 2026 | Asif Ali | CFO | Sale plan | 46,034 | $141.78 | $6.5M | Form 4 |
| Sep 10, 2026 | Dinesh V Ph D Patel | CEO | Sale plan | 7,278 | $144.10 | $1M | Form 4 |
| Sep 9, 2026 | Dinesh V Ph D Patel | CEO | Sale plan | 63,548 | $146.18 | $9.3M | Form 4 |
| Sep 8, 2026 | Dinesh V Ph D Patel | CEO | Sale plan | 54,174 | $145.87 | $7.9M | Form 4 |
| Aug 11, 2026 | Dinesh V Ph D Patel | CEO | Sale plan | 34,239 | $148.52 | $5.1M | Form 4 |
| Aug 10, 2026 | Dinesh V Ph D Patel | CEO | Sale plan | 65,761 | $149.11 | $9.8M | Form 4 |
| Jun 23, 2026 | William D. Waddill | Director | Sale plan | 9,000 | $117.94 | $1.1M | Form 4 |
| Jun 10, 2026 | William D. Waddill | Director | Sale plan | 9,000 | $107.68 | $969K | Form 4 |
| May 29, 2026 | William D. Waddill | Director | Sale plan | 9,000 | $99.64 | $897K | Form 4 |
| May 12, 2026 | Dinesh V Ph D Patel | CEO | Sale plan | 75,000 | $100.12 | $7.5M | Form 4 |
| May 8, 2026 | Bryan Giraudo | Director | Sale | 5,130 | $100.00 | $513K | Form 4 |
| May 8, 2026 | Bryan Giraudo | Director | Sale | 6,000 | $100.00 | $600K | Form 4 |
| May 7, 2026 | Bryan Giraudo | Director | Sale | 36,000 | $100.14 | $3.6M | Form 4 |
| May 7, 2026 | Bryan Giraudo | Director | Sale | 12,000 | $100.07 | $1.2M | Form 4 |
| Apr 20, 2026 | Asif Ali | CFO | Sale | 1,750 | $105.47 | $185K | Form 4 |
| Mar 26, 2026 | Arturo Md Molina | Chief Medical Officer | Sale | 15,000 | $104.79 | $1.6M | Form 4 |
| Mar 26, 2026 | Harold E Selick | Director | Sale | 24,000 | $105.00 | $2.5M | Form 4 |
| Mar 26, 2026 | Asif Ali | CFO | Sale | 24,765 | $104.24 | $2.6M | Form 4 |
| Mar 25, 2026 | Dinesh V Ph D Patel | CEO | Sale | 54,641 | $101.00 | $5.5M | Form 4 |
| Mar 24, 2026 | Dinesh V Ph D Patel | CEO | Sale | 59 | $101.00 | $6K | Form 4 |
| Feb 17, 2026 | Lewis T Williams | Director | Sale | 18,000 | $82.42 | $1.5M | Form 4 |
| Feb 6, 2026 | William D. Waddill | Director | Sale | 20,000 | $83.68 | $1.7M | Form 4 |
| Jan 27, 2026 | Dinesh V Ph D Patel | CEO | Sale | 4,068 | $83.19 | $338K | Form 4 |
| Jan 27, 2026 | Asif Ali | CFO | Sale | 28,000 | $83.13 | $2.3M | Form 4 |
| Jan 27, 2026 | Asif Ali | CFO | Sale | 18,203 | $83.14 | $1.5M | Form 4 |
| Jan 27, 2026 | Arturo Md Molina | Chief Medical Officer | Sale | 5,000 | $82.00 | $410K | Form 4 |
| Jan 26, 2026 | Dinesh V Ph D Patel | CEO | Sale | 10,685 | $84.00 | $898K | Form 4 |
| Jan 26, 2026 | Dinesh V Ph D Patel | CEO | Sale | 14,205 | $84.05 | $1.2M | Form 4 |
| Jan 26, 2026 | Arturo Md Molina | Chief Medical Officer | Sale | 5,000 | $82.28 | $411K | Form 4 |
| Jan 23, 2026 | Dinesh V Ph D Patel | CEO | Sale | 19,315 | $84.59 | $1.6M | Form 4 |
| Jan 23, 2026 | Arturo Md Molina | Chief Medical Officer | Sale | 13,151 | $82.42 | $1.1M | Form 4 |
| Jan 20, 2026 | Arturo Md Molina | Chief Medical Officer | Sale | 9,514 | $82.48 | $785K | Form 4 |
| Jan 20, 2026 | Dinesh V Ph D Patel | CEO | Sale | 34,438 | $82.48 | $2.8M | Form 4 |
| Jan 20, 2026 | Asif Ali | CFO | Sale | 8,588 | $82.48 | $708K | Form 4 |
| Nov 17, 2025 | Arturo Md Molina | Chief Medical Officer | Sale | 2,712 | $84.77 | $230K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Dinesh V Ph D Patel | President and CEO, Director | – | $53.1M | Sep 10, 2026 |
| Asif Ali | Chief Financial Officer | – | $15.6M | Sep 30, 2026 |
| Bryan Giraudo | Director | – | $5.9M | May 8, 2026 |
| William D. Waddill | Director | – | $4.6M | Jun 23, 2026 |
| Arturo Md Molina | Chief Medical Officer | – | $4.5M | Mar 26, 2026 |
| Harold E Selick | Director | – | $2.5M | Mar 26, 2026 |
| Lewis T Williams | Director | – | $1.5M | Feb 17, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
PTGX short interest
High short interest. 15.8% of PTGX shares are sold short: about 1 share in 6. Over the last 12 reports the number of shares short went up 40%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 10.24M PTGX shares were sold short, 15.8% of the shares outstanding, down 0.5% from the report before. At the average daily volume of 606,261 shares, buying them all back would take about 16.9 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 10.24M | 15.83% | -1% | 606,261 | 16.9 |
| Oct 15, 2026 | 10.30M | 15.91% | +10% | 856,448 | 12.0 |
| Sep 30, 2026 | 9.35M | 14.44% | +15% | 813,300 | 11.5 |
| Sep 15, 2026 | 8.14M | 12.58% | +6% | 538,023 | 15.1 |
| Aug 31, 2026 | 7.71M | 11.92% | -1% | 502,802 | 15.3 |
| Aug 14, 2026 | 7.79M | 12.04% | +3% | 474,581 | 16.4 |
| Jul 31, 2026 | 7.54M | 11.66% | -9% | 530,739 | 14.2 |
| Jul 15, 2026 | 8.29M | 12.89% | +8% | 870,374 | 9.5 |
| Jun 30, 2026 | 7.69M | 11.96% | -0% | 1.07M | 7.2 |
| Jun 15, 2026 | 7.73M | 12.02% | +4% | 666,636 | 11.6 |
| May 29, 2026 | 7.41M | 11.52% | +2% | 440,776 | 16.8 |
| May 15, 2026 | 7.29M | 11.34% | -3% | 571,831 | 12.8 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Protagonist Therapeutics company events
Protagonist Therapeutics filed 6 reports on Form 8-K in the last 12 months, 1 of them about an important change (leadership). The latest was on Nov 5, 2026.
- Nov 5, 2026ResultsReleased financial results. Filing
- Aug 5, 2026ResultsReleased financial results. Filing
- Jun 18, 2026LeadershipDeparture of Director or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Filing
- May 5, 2026ResultsReleased financial results. Filing
- Feb 25, 2026ResultsReleased financial results. Filing
- Jan 12, 2026AnnouncementShared information with investors. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Protagonist Therapeutics financials
Famous investors that hold PTGX
2 of the 50 well-known investors we track reported holding PTGX in their latest 13F filing. The largest position is Ken Fisher's, worth $23.7M.
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Ken Fisher · Fisher Asset Management | Q3 2026 | 168,373 | $23.7M | 0.0% | -1% |
| Jim Simons · Renaissance Technologies | Q3 2026 | 76,967 | $10.8M | 0.0% | New |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named PTGX in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Oct 27, 2026 | BlackRock, Inc. | 13G/A | 15.2% |
| Oct 27, 2026 | BlackRock, Inc. | 13G/A | 15.2% |
Questions about Protagonist Therapeutics, Inc (PTGX) stock
Who owns the most PTGX stock?
The largest reported owner of Protagonist Therapeutics, Inc (PTGX) is BlackRock, Inc., with 16.0% of the company. In total, 342 funds and institutions reported holding PTGX at the end of Q2 2026, together about 100% of the shares. See the largest owners.
Are PTGX insiders buying or selling?
In the last 12 months, PTGX insiders reported no open-market purchases and 36 sales worth $87.7M. The latest trade was on Sep 30, 2026. See every trade.
What is the short interest in PTGX?
As of Oct 30, 2026, 10.24M PTGX shares were sold short, 15.8% of the shares outstanding, down 0.5% from the report before. At the average daily volume of 606,261 shares, buying them all back would take about 16.9 trading days (days to cover). See the history.
Which famous investors hold PTGX?
2 of the 50 well-known investors we track reported PTGX in their latest 13F filing, including Ken Fisher, Jim Simons. The largest position is worth $23.7M. See all holders.
Executive pay
Protagonist Therapeutics's chief executive was paid a total of $12.9M for the year ended Dec 31, 2025, up 36% from $9.5M the year before. In the last 12 months, Protagonist Therapeutics's executives and directors bought no stock on the open market and sold $87.7M.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.